Acadia Pharmaceuticals | ACAD - Operating Expenses


Acadia Pharmaceuticals reported $270.57M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Corcept Therapeutics USD 225.75M 10.9M Sep/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
Eisai JPY 218.93B 9.33B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Incyte USD 5.64B 4.67B Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Moderna USD 1.18B 223M Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Prothena USD 19.7M 5.6M Jun/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026